Equity awards reshape C4 Therapeutics (CCCC) officer Kelly Schick’s share holdings

Rhea-AI Filing Summary

C4 Therapeutics Chief People Officer Kelly Schick reported several equity compensation transactions in Common Stock. Schick received a grant of 200,000 restricted stock units, with 100,000 vesting in three equal annual installments starting on February 13, 2027 and 100,000 vesting in full on February 13, 2029, subject to performance milestones. Additional shares were acquired through the vesting of previously granted RSUs and by exercising derivative securities, while 7,269 and 1,735 shares were withheld to cover tax obligations, which the company notes do not represent market sales. Following these transactions, Schick directly owned 299,881 shares of Common Stock.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Schick Kelly

Role Chief People Officer

Type	Security	Shares	Price	Value
Exercise	Common Stock	20,950	$0.00	--
Tax Withholding	Common Stock	7,269	$1.89	$14K
Grant/Award	Common Stock	200,000	$0.00	--
Exercise	Common Stock	5,000	$0.00	--
Tax Withholding	Common Stock	1,735	$1.89	$3K

Holdings After Transaction: Common Stock — 307,150 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schick Kelly

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A		200,000(1)	A	$0	308,885	D
Common Stock	02/13/2026		M(2)	V	5,000	A	$0	308,885	D
Common Stock	02/13/2026		F(3)		1,735	D	$1.89	307,150	D
Common Stock	02/14/2026		M(2)	V	20,950	A	$0	307,150	D
Common Stock	02/14/2026		F(3)		7,269	D	$1.89	299,881	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.

2. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.

3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did C4 Therapeutics (CCCC) report for Kelly Schick?

C4 Therapeutics reported that Chief People Officer Kelly Schick received a 200,000-share RSU grant, acquired additional shares from vesting and exercises, and had shares withheld for taxes. These movements are part of equity compensation rather than open-market stock trading.

How many restricted stock units were granted to Kelly Schick of C4 Therapeutics (CCCC)?

Kelly Schick was granted 200,000 restricted stock units in total. 100,000 RSUs vest in three equal annual installments beginning February 13, 2027, and the remaining 100,000 RSUs vest in full on February 13, 2029, subject to performance milestones being achieved.

How do the new RSUs for C4 Therapeutics (CCCC) vest over time?

The 200,000 RSUs granted to Kelly Schick vest in two tranches. 100,000 vest in three equal annual installments starting February 13, 2027, while 100,000 vest in full on February 13, 2029, contingent on achieving specified performance milestones.

Were any of Kelly Schick’s C4 Therapeutics (CCCC) transactions open-market sales?

No open-market sales were reported. Shares shown as dispositions were withheld by C4 Therapeutics to satisfy tax withholding obligations upon RSU vesting, and the company states these withholdings do not represent sales by Kelly Schick in the market.

How many C4 Therapeutics (CCCC) shares does Kelly Schick own after these transactions?

After the reported equity compensation transactions, Kelly Schick directly owned 299,881 shares of C4 Therapeutics Common Stock. This figure reflects RSU vesting, option or derivative exercises, and share withholdings for tax obligations associated with those awards.

What do the tax-withholding share dispositions mean for C4 Therapeutics (CCCC) insider activity?

The tax-withholding dispositions reflect shares withheld by C4 Therapeutics to cover tax obligations when RSUs vested. According to the disclosure, these withholdings are administrative and do not represent discretionary sales or open-market selling decisions by Kelly Schick.